Results 11 to 20 of about 2,363,412 (175)
TRUE RESISTANCE AND PSEUDORESISTANCE TO ASPIRIN [PDF]
Рациональная фармакотерапия в кардиологии, 2015 Low dose aspirin reduces the secondary incidence of myocardial infarction and stroke. Drug resistance to aspirin might result in treatment failure.
A. I. Martynov +3 more
doaj +4 more sources
Platelets, 2018 Essential thrombocythemia (ET) and polycythemia vera (PV) are myeloproliferative neoplasms (MPN) with an increased risk of arterial and venous thrombosis.
Andréas Perrier-Cornet +5 more
doaj +2 more sources
Factors associated with aspirin resistance in diabetic patients: A metabolic and inflammatory profile analysis. [PDF]
PLoS ONEBackgroundDiabetes mellitus (DM) is strongly linked to both first-time and recurrent atherosclerotic thrombotic events. Although aspirin (ASA) is commonly used to prevent cardiovascular diseases, studies have shown that ASA does not significantly reduce ...
Bo Chen +5 more
doaj +2 more sources
Aspirin Resistance: Does It Exist?
Seminars in Thrombosis and Hemostasis, 2007 Aspirin irreversibly inhibits platelet cyclooxygenase-1 (COX-1). Aspirin sensitivity can be measured easily by its inhibition of arachidonic acid (AA) -induced platelet aggregation. Aspirin resistance has to be defined by its inability to inhibit COX-1. By using this definition, aspirin resistance very likely does not exist. A specific rapid laboratory
Rao, Gundu H.R., Michiels, Jan Jacques
openaire +4 more sources
The association between aspirin resistance and extent and severity of coronary atherosclerosis [PDF]
İstanbul Kuzey Klinikleri, 2018 INTRODUCTION[|]Uncontrolled inflammatory responses could contribute to the pathogenesis of many leading causes of human morbidity and mortality. Aspirin is an anti-inflammatory and antithrombotic drug that is used in the primary and secondary protection ...
Serkan Kahraman +5 more
doaj +2 more sources
Aspirin: yesterday, today, and tomorrow [PDF]
Pediatria i Medycyna Rodzinna, 2014 Clinical utility of aspirin (acetylsalicylic acid, ASA) is one of the more important issues in the primary and secondary prevention of cardiovascular disease.
Marina Nikołajewna Dołżenko
doaj +2 more sources
Aspirin and clopidogrel resistance: methodological challenges and opportunities
Vascular Health and Risk Management, 2010 Armen Yuri GasparyanClinical Research Unit, Russell’s Hall Hospital, Dudley Group of Hospitals NHS Foundation Trust, West Midlands, UKAbstract: Antiplatelet drug resistance is one of the urgent issues in current cardiovascular medicine.
Armen Yuri Gasparyan
doaj +1 more source
A contemporary viewpoint on ‘aspirin resistance’
Annals of Medicine, 2012 Aspirin is an irreversible inhibitor of platelet prostaglandin synthase activity, and is the most widely prescribed drug for the secondary prevention of cardiovascular disease. In recent years, clinical and laboratory evidence has shown significant individual variability in the response to aspirin and its link to clinical outcome.
Nadzeya, Kuzniatsova +3 more
openaire +3 more sources
British Journal of Surgery, 2002 OBJECTIVE: To review the literature addressing the problem of aspirin resistance in patients with vascular disease. DATA SOURCES: A MEDLINE search (1966–February 2002) was performed.
J, Smout, G, Stansby
+7 more sources
The prevalence and associated factors of aspirin resistance among prophylactic aspirin users [PDF]
Romanian Journal of Neurology, 2021 Background. Aspirin is an antiplatelet used for the secondary prevention after vascular events. It is also suggested for the primary prevention of vascular events in high risk people, however, despite using standard prophylactic doses, aspirin resistance
Samaneh Ghorbani-Shirkouhi +5 more
doaj +1 more source